Electrochromic + Anti-Fog Personal-Protective Eyewear (PPE) Based on Unique, Very Low Power, Conductive Coatings and Leveraging Unique, ANSI Z87.1-/Military-Qualified Electrochromic Eyewear Technology
电致变色防雾个人防护眼镜 (PPE) 基于独特的超低功耗导电涂层,并利用独特的 ANSI Z87.1/军用合格电致变色眼镜技术
基本信息
- 批准号:9406899
- 负责人:
- 金额:$ 54.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-01 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
With regard to Personal Protective Eyewear (PPE) technologies, a major occupational hazard in high risk
industrial sectors such as manufacturing, mining, construction, warehousing, environmental remediation/-
cleanup and biomedical cleanup (e.g. in Ebola work), but one which has received very limited attention to date,
is that associated with the worker transitioning from very bright to dark areas; fogging of the PPE
exacerbates the situation. Per recent OSHA statistics, the number of fatal accidents potentially caused by
light/dark (L/D) plus fogging issues may be up to 35% of the total (4,383 in 2012, 3.2/100,000 workers), with
non-fatal accidents having a similar proportion. In biohazard work, the suit wearer critically needs automated,
hands-free L/D plus antifogging control. Current PPE technologies for L/D control (e.g. photochromics
changing color with UV light, not working indoors or in cars), clip-on sunshades or extra sunglasses, and for
antifogging (e.g. superhydrophilic coatings or double-pane polycarbonate), are all grossly inadequate. Indeed,
the US Army Public Health Command specifically prohibits photochromics or clip-ons for military personnel.
Now in very recent prior and ongoing work, this firm has developed and patented a new electrochromics
technology, based on unique, matched-dual-polymer Conducting Polymer electrochromics (which change color
with small, e.g. 5 VDC, voltage); this has excellent performance, overcoming drawbacks preventing practical,
commercial electrochromic eyewear heretofore. Typical performance: L/D contrast 1% to 70% (vs. air
reference); thin (< 0.4 mm), flexible, durable construction; unique applied-voltage algorithm residing on an
inexpensive (<$8) Microcontroller yielding switching times of < 2 s LD, ~instantaneous DL; automated-
function (photosensor-based, rechargeable Li battery-powered); very low power (72 h with 12 L/D/L switches
per h before batteries need recharging; 15 µW/cm2, +/- 3.0 VDC); conforming to ANSI Z87.1-2010 and US
military (APEL) specifications. Furthermore, this firm has also developed a unique, active defogging
technology. In the Phase I work, these two technologies (electrochromics + defogging) were combined, with
spectacles/-goggles demonstrated having excellent electrochromic performance, active defogging in < 4
seconds, and very low power consumption. A preliminary CAD design for final-form eyewear was arrived at.
Proposed Phase II work will: (1) Further optimize performance of these spectacles/goggles, including control,
power consumption, defog performance. (2) Demonstrate their function with full-body biomedical suits. (3)
Design and set up a semi-automated, pilot production line for 100 spectacles/-goggles per month, leveraging
the firm’s just-initiated commercial production of its standard (not defogging) electrochromic sunglasses. (4)
Establish commercialization tie-ups with partners identified. If successful, the inexpensive (<$80) product
resulting from this work will be the first commercially viable electrochromics + defogging eyewear, drastically
upgrading PPE. Ancillary markets (skiwear, motor sports, bicycling, football, military) may further lower cost.
关于个人防护眼镜(PPE)技术,是一项高风险的重大职业危害
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PRASANNA CHANDRASEKHAR其他文献
PRASANNA CHANDRASEKHAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PRASANNA CHANDRASEKHAR', 18)}}的其他基金
Fast-Switching, High-Contrast, Electrochromic Sunwear for Persons with Age-Relate
适合年龄相关人士的快速切换、高对比度、电致变色太阳镜
- 批准号:
8860085 - 财政年份:2011
- 资助金额:
$ 54.38万 - 项目类别:
Fast-Switching, High-Contrast, Electrochromic Sunwear for Persons with Age-Relate
适合年龄相关人士的快速切换、高对比度、电致变色太阳镜
- 批准号:
8589501 - 财政年份:2011
- 资助金额:
$ 54.38万 - 项目类别:
Fast-Switching, High-Contrast, Electrochromic Sunwear for Persons with Age-Relate
适合年龄相关人士的快速切换、高对比度、电致变色太阳镜
- 批准号:
8121240 - 财政年份:2011
- 资助金额:
$ 54.38万 - 项目类别:
MICROWAVE REMEDIATION OF HAZARDOUS MEDICAL WASTES
危险医疗废物的微波修复
- 批准号:
7682081 - 财政年份:2005
- 资助金额:
$ 54.38万 - 项目类别:
MICROWAVE REMEDIATION OF HAZARDOUS MEDICAL WASTES
危险医疗废物的微波修复
- 批准号:
7536453 - 财政年份:2005
- 资助金额:
$ 54.38万 - 项目类别:
ELECTROCHROMIC FAST DARKENING SUNWEAR FOR PEOPLE ARMD
适合手臂的电致变色快速变光太阳镜
- 批准号:
6384739 - 财政年份:1998
- 资助金额:
$ 54.38万 - 项目类别:
相似国自然基金
基于spA-Gel负载Anti-HMGB1原位靶向免疫耐受的猪胰岛类器官移植研
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
肺癌外周血淋巴细胞亚群预测anti-PD1/PDL1疗效的鉴定及应用研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
TKIs氘代化修饰通过促进HCC铁死亡增强免疫原性并增敏anti-PD-1治疗的机制研究
- 批准号:JCZRQN202500319
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
Anti-MDA5阳性皮肌炎病人的NK细胞数量与功能改变在间质性肺疾病中的作用与机制研究
- 批准号:MS25H100014
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
特发性膜性肾病血清标志物anti-PLA2R-IgG4检测方法的建立及临床应用
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
经 anti-GPC3 修饰的外泌体靶向递送索拉非尼与放疗联合诱
导肝细胞癌铁死亡的研究
- 批准号:2024JJ9608
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
CCL2介导PGK1的O-GlcNAc糖基化修饰诱导CAFs代谢重编程促进头颈癌anti-PD-1免疫治疗耐药的机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
千金藤素通过自噬损伤导致的免疫原性细胞死亡促进 anti-PD1 治疗MSS 型结直肠癌的疗效与机制研究
- 批准号:
- 批准年份:2024
- 资助金额:10.0 万元
- 项目类别:省市级项目
周细胞 ZEB1/SPP1 旁分泌轴招募 MDSCs 诱导
卵巢癌 anti-PD1/PD-L1 疗法耐药的机制研究
- 批准号:Y24H310009
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
肿瘤相关成纤维细胞通过 YAP/CXCL12 信号
轴调控 B 细胞功能介导肝癌anti-PD1治疗抵
抗的机制研究
- 批准号:TGY24H160070
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
相似海外基金
Lipid nanoparticle-mediated Inhalation delivery of anti-viral nucleic acids
脂质纳米颗粒介导的抗病毒核酸的吸入递送
- 批准号:
502577 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Anti-senescence ADSCを用いた変形性膝関節症に対する新しい細胞治療法の開発
利用抗衰老 ADSC 开发治疗膝骨关节炎的新细胞疗法
- 批准号:
24K19596 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Anti-infective therapeutics and predictive modelling to tackle Staphylococcus aureus disease
应对金黄色葡萄球菌疾病的抗感染疗法和预测模型
- 批准号:
EP/X022935/2 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Fellowship
Identification of genes responsible for the resistance to first line anti-myeloma therapeutics
鉴定导致一线抗骨髓瘤治疗耐药的基因
- 批准号:
24K11532 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation
用于生物正交抗癌前药激活的抗体-钯缀合物
- 批准号:
EP/Y024540/1 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Fellowship
A novel anti-biofilm peptide from fish for the combat against antimicrobial resistance
一种来自鱼类的新型抗生物膜肽,用于对抗抗菌素耐药性
- 批准号:
MR/Y503393/1 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Research Grant
Anti-racist neuroethics for epistemic justice in mental health research
心理健康研究中认知正义的反种族主义神经伦理学
- 批准号:
DE240100386 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Discovery Early Career Researcher Award
Presymptom: development of a novel machine-learning-derived diagnostic test to rule out infection to enable enhanced clinical care and better targeted anti-microbial use
症状前:开发一种新型的机器学习诊断测试来排除感染,从而加强临床护理和更有针对性的抗菌药物使用
- 批准号:
10089281 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Investment Accelerator
Lignin-based coatings: A novel approach to turn challenges into opportunities for anti-corrosion and anti-wear applications
木质素涂料:一种将防腐和抗磨损应用挑战转化为机遇的新方法
- 批准号:
EP/Y022009/1 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Research Grant
Application of the virus-like particle (VLP) technology in the development of anti-tick vaccine, utilizing novel salivary proteins from Haemaphysalis longicornis ticks.
利用长角血蜱的新型唾液蛋白,应用病毒样颗粒(VLP)技术开发抗蜱疫苗。
- 批准号:
24K18027 - 财政年份:2024
- 资助金额:
$ 54.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists